

PRELIMINARY AMENDMENT  
CONT. of PCT/NO98/00134

Page 5, after line 5, insert

-- DETAILED DESCRIPTION OF THE INVENTION --

Page 9, after line 27, insert

-- BRIEF DESCRIPTION OF THE DRAWINGS --.

Page 12, after line 32, insert

-- EXAMPLES --.

Page 31, line 9, change "immunodeficiencies" to  
-- immunodeficiencies --.

IN THE CLAIMS:

Please delete Claims 1-21.

Please add the following new claims:

*SUB B*  
*100*  
*00*  
*00*  
*00*  
*00*

-- Claim 22. A pharmaceutical composition useful for treating an immunosuppressive disease comprising (A) a pharmaceutically effective amount of an inhibitor selected from the group consisting of a cAMP antagonist, a hammerhead ribozyme, a sequence specific antisense oligonucleotide and an anchoring disruption peptide, wherein said inhibitor selectively or specifically abolishes the function of cAMP dependent protein kinase (PKA) type I $\alpha$  isozyme (RI $\alpha$ <sub>2</sub>C<sub>2</sub>) ; and (B) a pharmaceutically acceptable adjuvant or filler.

Claim 23. The pharmaceutical composition according to Claim 22, wherein said cAMP antagonist is a thio-substituted cAMP analog, wherein said thio-substituted cAMP analog is an equatorial diastereomer of 3',5'-cyclic adenosine monophosphorothioate (Rp-cAMPS), and wherein said thio-substituted cAMP analog binds to an RI $\alpha$  subunit of said isozyme and acts as a selective or specific antagonist of said isozyme.

PRELIMINARY AMENDMENT  
CONT. of PCT/NO98/00134

Claim 24. The pharmaceutical composition according to Claim 23, wherein said cAMP antagonist is selected from the group consisting of Rp-8-Br-cAMPS and Rp-8-Cl-cAMPS.

Claim 25. The pharmaceutical composition according to Claims 22, wherein said hammerhead ribozyme comprises the nucleotide base sequence of SEQ ID NO:5.

Claim 26. The pharmaceutical composition according to Claim 22, wherein said hammerhead ribozyme comprises the nucleotide base sequence of SEQ ID NO:6.

Claim 27. The pharmaceutical composition according to Claim 22, wherein said hammerhead ribozyme contains 2-deoxy-cytosine substitution(s) for cytosine or 2-deoxy-uracil substitution(s) for uracil, in an amount sufficient to stabilize said hammerhead ribozyme.

Claim 28. The pharmaceutical composition according to Claim 22, wherein said sequence specific antisense oligonucleotide has the nucleotide base sequence of SEQ ID NO:7.

Claim 29. The pharmaceutical composition according to Claim 22, wherein said sequence specific antisense nucleotide comprises the nucleotide base sequence of SEQ ID NO:8.

Claim 30. The pharmaceutical composition according to Claim 22, wherein said anchoring disruptive peptide comprises 22 amino acids.

Claim 31. The pharmaceutical composition according to Claim 30, wherein said anchoring disruptive peptide comprises the amino acid sequence of SEQ ID NO:1.

PRELIMINARY AMENDMENT  
CONT. of PCT/NO98/00134

Claim 32. The pharmaceutical composition according to Claim 30, wherein said anchoring disruptive peptide comprises the amino acid sequence of SEQ ID NO:2.

Claim 33. The pharmaceutical composition according to Claim 30, wherein said anchoring disruptive peptide comprises the amino acid sequence of SEQ ID NO:3.

Claim 34. The pharmaceutical composition according to Claim 30, wherein said anchoring disruptive peptide comprises the amino acid sequence of SEQ ID NO:4.

Claim 35. The pharmaceutical composition according to Claim 22, wherein said immunosuppressive disease is selected from the group consisting of AIDS, HIV infection and CVI.

Claim 36. A hammerhead ribozyme useful for disrupting expression of RI $\alpha$  subunit of PKA type I $\alpha$  isozyme, comprising an amino acid sequence selected from the group consisting of SEQ ID NO:5 and SEQ ID NO:6.

Claim 37. An antisense oligonucleotide useful for disrupting expression of RI $\alpha$  subunit of PKA type I $\alpha$  isozyme, comprising a nucleotide base sequence selected from the group consisting of SEQ ID NO:7 and SEQ ID NO:8.

*Sub B2* Claim 38. A method of inhibiting the effects mediated by PKA type I $\alpha$  isozyme comprising administering to subject in need of said inhibition, the pharmaceutical composition of any of Claims 23-34, so as to inhibit the localization of PKA type I $\alpha$  isozyme with T cell receptor/CD3 complexes.

Claim 39. The method according to Claim 38, wherein said subject is afflicted with an immunosuppressive disease selected from the group consisting of AIDS, HIV infection and CVI. --